Gary R. Sitko

United States Military Academy — United States

Medicine · Health Sciences

19h-index1.1kcitations38works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Platelet Disorders and Treatments(18), Antiplatelet Therapy and Cardiovascular Diseases(14), Blood Coagulation and Thrombosis Mechanisms(11), Heparin-Induced Thrombocytopenia and Thrombosis(9), Monoclonal and Polyclonal Antibodies Research(4)

Publications38 total

Development and characterization of a nerve conduction model in anesthetized non-human primates as a tool to assess compound-dependent peripheral nervous system risk
Journal of Pharmacological and Toxicological Methods·2019
Differential anti-thrombotic benefit and bleeding risk profiles of antagonists of protease-activated receptor 1 and 4 in Cynomolgus Macaques
Thrombosis Research·2016· 2 cited
Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist
European Journal of Pharmacology·2015· 16 cited
α-Hydroxy amides as a novel class of bradykinin B1 selective antagonists
Bioorganic & Medicinal Chemistry Letters·2007· 27 citedOpen Access
P2–069: Nonhuman primate model for prediction of human Aβ effects. Targeting γ–secretase: Effects of enzyme inhibition vs. modulation of cleavage specificity on CSF and plasma Aβ in conscious rhesus monkeys
Alzheimer s & Dementia·2006· 5 cited
Thrombin in complex with an azafluorenyl inhibitor 23b
2005
Determination of potato carboxypeptidase inhibitor in African Green Monkey plasma using 96-well SPE and LC–MS/MS
Journal of Pharmaceutical and Biomedical Analysis·2005· 9 cited
9-Hydroxyazafluorenes and Their Use in Thrombin Inhibitors
Journal of Medicinal Chemistry·2005· 36 citedOpen Access
Synthesis and Evaluation of Imidazole Acetic Acid Inhibitors of Activated Thrombin-Activatable Fibrinolysis Inhibitor as Novel Antithrombotics
Journal of Medicinal Chemistry·2003· 42 citedOpen Access
Metabolism-Directed Optimization of 3-Aminopyrazinone Acetamide Thrombin Inhibitors. Development of an Orally Bioavailable Series Containing P1 and P3 Pyridines
Journal of Medicinal Chemistry·2003· 120 citedOpen Access
Crystal Structure of Thrombin in Complex with L-378,622
2002
Non-Peptide GPIIb/IIIa Inhibitors. 20. Centrally Constrained Thienothiophene α-Sulfonamides Are Potent, Long Acting in Vivo Inhibitors of Platelet Aggregation
Journal of Medicinal Chemistry·1999· 2 cited
Non-Peptide GPIIb/IIIa Inhibitors. 20. Centrally Constrained Thienothiophene α-Sulfonamides Are Potent, Long Acting in Vivo Inhibitors of Platelet Aggregation
Journal of Medicinal Chemistry·1999· 50 citedOpen Access
Antithrombotic Efficacy of Thrombin Inhibitor L-374,087: Intravenous Activity in a Primate Model of Venous Thrombus Extension and Oral Activity in a Canine Model of Primary Venous and Coronary Artery Thrombosis
Journal of Pharmacology and Experimental Therapeutics·1999· 13 cited
Effects of pentobarbital on pharmacokinetics and pharmacodynamics of a potent fibrinogen receptor antagonist, L-734 217, in dogs
Biopharmaceutics & Drug Disposition·1997· 3 cited
ChemInform Abstract: Nonpeptide Glycoprotein IIb/IIIa Inhibitors. Part 13. Design and Synthesis of an Orally Active Pyrazolopiperazinone Nonpeptide Fibrinogen Receptor Antagonist.
ChemInform·1997
ChemInform Abstract: Nonpeptide GPIIb/IIIa Inhibitors. Part 16. Thieno(2,3‐b)thiophene . alpha.‐Sulfonamides are Potent Inhibitors of Platelet Aggregation.
ChemInform·1997
Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury.
PubMed·1997· 13 cited
Non-Peptide Glycoprotein IIb/IIIa Inhibitors. 17. Design and Synthesis of Orally Active, Long-Acting Non-Peptide Fibrinogen Receptor Antagonists
Journal of Medicinal Chemistry·1997· 56 citedOpen Access
Nonpeptide glycoprotein IIb/IIIa inhibitors. 13. design and synthesis of an orally active pyrazolopiperazinone nonpeptide fibrinogen receptor antagonist
Bioorganic & Medicinal Chemistry Letters·1997· 26 cited
page 1 of 2Next →

Frequent Co-authors

Marie A. Holahan(26), Jacquelynn J. Cook(25), Joseph J. Lynch(21), Maria T. Stranieri(21), Robert J. Lynch(14), George D. Hartman(13), R J Gould(9), Audrey A. Wallace(8), Bohumil Bednář(8), Rodney A. Bednar(8), Robert J. Gould(7), Stanley L. Gaul(7), Joan D. Glass(6), Denise Ramjit(5), Cynthia Miller‐Stein(5), Daniel R. McMasters(5), Yvonne Leonard(5), Inez I. Stabilito(4), Bobby J. Lucas(4), Julie A. Krueger(4)